+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Pharming Group NV - logo

The Pharming Group offers novel platforms for the production of protein therapeutics, as well as processes for the purification and formulation. The company’s best known product is Ruconest, a human C1 inhibitor. Human C1 inhibitor is a protein involved in the regulation of the complement and contact pathways of the immune system. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

From
From
Hereditary Angioedema Therapeutics Market 2023-2027 - Product Thumbnail Image

Hereditary Angioedema Therapeutics Market 2023-2027

  • Report
  • July 2023
  • 156 Pages
  • Global
From
Angioedema - Pipeline Insight, 2024 - Product Thumbnail Image

Angioedema - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 80 Pages
  • Global
From
From
From
Fibrin Sealants Market 2024-2028 - Product Thumbnail Image

Fibrin Sealants Market 2024-2028

  • Report
  • June 2024
  • 146 Pages
  • Global
From
From
Plasma Protease C1 Inhibitor Market 2024-2028 - Product Thumbnail Image

Plasma Protease C1 Inhibitor Market 2024-2028

  • Report
  • January 2024
  • 166 Pages
  • Global
From
Immunologic Deficiency Syndrome - Pipeline Insight, 2024 - Product Thumbnail Image

Immunologic Deficiency Syndrome - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Complement C1s inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

Complement C1s inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
Loading Indicator